Efficacy and safety of Adalimumab in patients with moderate to severe hidradenitis suppurativa: Results from PIONEER II, a phase 3 randomised placebo-controlled trial

Authors
Category Primary study
ConferenceAustralasian Journal of Dermatology
Year 2015
This article has no abstract
Epistemonikos ID: 983a46b10d69246335941b1ed50b842391d55a6b
First added on: Apr 30, 2026